340B Drug Pricing Program
The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on its request for information on whether to implement a 340B rebate model program. Comments on the RFI were originally due March 19.
The U.S. District Court for the District of Hawaii Feb. 23 denied a preliminary injunction requested by AstraZeneca in a case challenging the state’s law protecting 340B pricing for contract pharmacy arrangements. The court held that Hawaii’s law is not preempted by the federal law, does not…
The Health Resources and Services Administration today said it will extend the deadline to April 20 to receive comments.
HRSA has extended comment deadline and suggested a significantly expanded scope of rebate program.
Hospitals should submit letters to HRSA by March 19.
While the AHA broadly supports the Administration’s objectives as described in the proposed rule, we believe the GLOBE Model as proposed lacks critical operational details that, if not properly clarified, could create additional burden for hospitals and health systems.
It is critical that HRSA hear from as many 340B hospitals as possible about the costs and administrative burdens a rebate model program would impose.
The AHA, joined by several other national groups representing 340B hospitals, Feb. 19 urged the Health Resources and Services Administration to extend the timeline for stakeholders to submit comments to the agency’s recent request for information on a new 340B rebate model program.
The American Hospital Association 340B Advocacy Alliance Bulletin for February 19, 2026.
The American Hospital Association's initial comment on the Health Resources and Services Administration’s (HRSA) request for information regarding a 340B Rebate Model Pilot Program.